We breathe new life
into osteoarthritic joints
Doron Therapeutics is a clinical-stage biotechnology company that has developed a Phase 3 ready, intra-articular biologic drug derived from placental tissue. The lead product, MOTYS™, consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective and regenerative capabilities pivotal to the progressive and degenerative disease of osteoarthritis.
Introducing, MOTYS™:
A new biologic
Every day at Doron Therapeutics, we strive to develop and deliver biotechnologies that help people get moving again. MOTYS™ — from the Latin word motus, meaning motion — marks a significant leap forward: derived from placental tissue, it is rich in relevant growth factors, holds remarkable potential, and is reliable in its consistency.
Contact Us
Our team can help to answer any of your questions.
Get in touch to learn more about Doron Therapeutics.